NCT02042781View on ClinicalTrials.gov

Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

September 30, 2016

Conditions
Advanced Solid Tumours
Interventions
DRUG

PG545

PG545 will be administered once weekly, as a one hour IV infusion. Patients will be treated until they exhibit disease progression, withdraw due to poor tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 250 mg anticipated.

Trial Locations (2)

3004

Nucleus Network Ltd, Melbourne

6009

Linear Clinical Research Ltd, Nedlands

All Listed Sponsors
lead

Zucero Pty Ltd

INDUSTRY

NCT02042781 - Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours | Biotech Hunter | Biotech Hunter